DVM
Dược liệu Việt Nam ·HNX ·2026Q1
▼▼ Declining sharply
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, DVM is losing revenue quickly, though margins have not been hit proportionally yet — profit is at an all-time high. This only holds if margins can continue to resist — if revenue stays weak, margin pressure will build.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.0 | 423.0 | 330.1 | 378.0 | 319.8 | 406.9 | 456.7 | 322.5 | 393.8 | 528.7 | 341.7 | 364.9 |
| Growth | -88% | +28% | -13% | +18% | -21% | -11% | +42% | -18% | -26% | +55% | -6% | — |
| Net Income | 0.2 | 10.0 | 8.1 | 14.8 | 12.3 | 12.0 | 18.2 | 11.6 | 8.3 | 5.9 | 11.2 | 17.4 |
| Net Margin | 0.38% | 2.37% | 2.45% | 3.92% | 3.85% | 2.94% | 3.98% | 3.61% | 2.10% | 1.11% | 3.28% | 4.76% |
Drivers of DVM's profit
Net profit attributable to parent declined vs last year, mainly due to lower gross profit. Supporting and offsetting drivers:
Net profit attributable to parent declined vs prior quarter, mainly due to lower gross profit. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE fell from 7.5% to 4.3% — all three components weakened, with asset turnover being the main drag.
Is the profit sustainable?
Margins narrowed but earnings quality remains clean — pressure is mainly operational.
What is driving the margin?
Net margin narrowed to 2.80%, falling 0.8pp. The main pressure comes from Gross margin fell 0.6pp and SG&A / Revenue rose 0.3pp (in addition, Other profit / Revenue rose 0.1pp added support while Net financial result / Revenue fell 0.0pp remained a drag).
The pressure comes from core operations — this is a concerning type of decline, not a one-off movement.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Capital efficiency is declining — check whether the drag is from margins or turnover.
Is capital being deployed efficiently?
ROIC fell to 2.66%, losing 1.5pp. That translates to 2.66 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin narrowed 0.9pp and capital turnover fell 0.19x, with invested capital easing slightly by 66bn — pressure came from both operational efficiency and asset efficiency.
Both margin and turnover weakened — this is a broad-based decline, and cyclical versus structural components need to be separated.
Watchpoints
ROIC is currently 2.66% — below the typical cost-of-capital threshold; worth tracking whether upcoming periods can rise above this level.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC declined — the balance sheet shows how capital is being deployed. Capital structure is balanced — liabilities at 1.13x equity, net debt at 0.60x equity.
Over the last 12 months, working capital released 0.0bn of cash.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 5.3 days versus the same period last year. The main moves came from DIO fell 6.3 days, DSO rose 29.9 days, and DPO rose 28.9 days.
Improvement comes mainly from faster receivables collection — reflects the quality of receivables management.
Watchpoints
CCC stands at 133.9 days, suggesting that working capital remains tied up for a relatively long operating cycle.
DSO increased by +29.9 days, pointing to slower receivables turnover.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Check leverage, liquidity, and cash-flow conversion.
Leverage & Liquidity
Leverage warrants monitoring, with net debt / equity at 0.60x and interest coverage only at 1.20x.
At present, short-term debt accounts for 97.2% of total debt, cash equals 0.8% of debt, and total debt stands at 467.3bn.
Watchpoints
Interest coverage is 1.20x, leaving limited room to absorb financing costs.
Short-term debt accounts for 97.2% of total debt, raising near-term refinancing needs.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 1,124.0bn in 2025, against investing cash flow of 80.2bn.
Post-investment cash flow was positive +1,204.1bn. Financing cash flow was negative +1,176.2bn.
CFO / net income was 31.01x.
Track how much investment can be funded internally from operating cash flow.
Cash capex or FCF data is incomplete, so the cash-conversion view is only partial.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is showing a few weaker signals, but the current magnitude is not yet clear enough to conclude that this is a broader weakening phase. The brighter spot is earnings conversion is confirmed, with CFO/NI at 31.01x. The next item to monitor is cash generation still needs confirmation. The main risk still sits in capital efficiency remains weak, with ROIC at 2.7%.
Improvement: earnings conversion looks more confirmed, with CFO / net income at 31.01x.
Watchpoint: Cash generation still needs confirmation.
Key risk: Capital efficiency remains weak.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Net Revenue
|
1,450.9 | 1,580.0 | 1,481.7 | 1,179.0 |
|
Cost of Goods Sold
|
1,311.0 | 1,439.4 | 1,323.5 | 1,013.8 |
|
Gross Profit
|
139.9 | 140.6 | 158.2 | 165.2 |
|
Financial Expenses
|
42.4 | 47.7 | 58.9 | 44.1 |
|
Selling Expenses
|
6.9 | 11.3 | 25.7 | 31.9 |
|
General and Administrative Expenses
|
41.9 | 28.4 | 30.8 | 28.7 |
|
Operating Profit
|
50.1 | 57.8 | 49.0 | 63.4 |
|
Profit Before Tax
|
47.0 | 55.4 | 49.5 | 63.7 |
|
Net Income
|
40.0 | 47.9 | 43.2 | 54.4 |
|
Profit Attributable to Parent
|
40.0 | 47.9 | 43.2 | 54.4 |
|
Earnings per Share
|
921.00 | 1,119.00 | 1,211.00 | 1,648.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.